Advances in developing therapies to combat zika virus: Current knowledge and future perspectives

Ashok Munjal, Rekha Khandia, Kuldeep Dhama, Swati Sachan, Kumaragurubaran Karthik, Ruchi Tiwari, Yashpal S. Malik, Deepak Kumar, Raj K. Singh, Hafiz M.N. Iqbal, Sunil Joshi

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international "public health emergency" in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barré syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV.

Original languageEnglish (US)
Article number1469
JournalFrontiers in Microbiology
Volume8
Issue numberAUG
DOIs
StatePublished - Aug 3 2017
Externally publishedYes

Fingerprint

Antibody-Dependent Enhancement
Therapeutics
Drug Repositioning
Public Health
Virus Internalization
Microcephaly
Herbal Medicine
Toll-Like Receptors
Methyltransferases
Viral Proteins
Drug Delivery Systems
Neutralizing Antibodies
Nucleosides
Pharmaceutical Preparations
Interferons
Virulence
Zika Virus
Proteins
Emergencies
Vaccines

Keywords

  • Drugs
  • Guillain-Barré Syndrome
  • Microcephaly
  • Therapies
  • Zika virus

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Advances in developing therapies to combat zika virus : Current knowledge and future perspectives. / Munjal, Ashok; Khandia, Rekha; Dhama, Kuldeep; Sachan, Swati; Karthik, Kumaragurubaran; Tiwari, Ruchi; Malik, Yashpal S.; Kumar, Deepak; Singh, Raj K.; Iqbal, Hafiz M.N.; Joshi, Sunil.

In: Frontiers in Microbiology, Vol. 8, No. AUG, 1469, 03.08.2017.

Research output: Contribution to journalReview article

Munjal, A, Khandia, R, Dhama, K, Sachan, S, Karthik, K, Tiwari, R, Malik, YS, Kumar, D, Singh, RK, Iqbal, HMN & Joshi, S 2017, 'Advances in developing therapies to combat zika virus: Current knowledge and future perspectives', Frontiers in Microbiology, vol. 8, no. AUG, 1469. https://doi.org/10.3389/fmicb.2017.01469
Munjal, Ashok ; Khandia, Rekha ; Dhama, Kuldeep ; Sachan, Swati ; Karthik, Kumaragurubaran ; Tiwari, Ruchi ; Malik, Yashpal S. ; Kumar, Deepak ; Singh, Raj K. ; Iqbal, Hafiz M.N. ; Joshi, Sunil. / Advances in developing therapies to combat zika virus : Current knowledge and future perspectives. In: Frontiers in Microbiology. 2017 ; Vol. 8, No. AUG.
@article{94053df6cbd94429bb1c725ad0a36069,
title = "Advances in developing therapies to combat zika virus: Current knowledge and future perspectives",
abstract = "Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international {"}public health emergency{"} in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barr{\'e} syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV.",
keywords = "Drugs, Guillain-Barr{\'e} Syndrome, Microcephaly, Therapies, Zika virus",
author = "Ashok Munjal and Rekha Khandia and Kuldeep Dhama and Swati Sachan and Kumaragurubaran Karthik and Ruchi Tiwari and Malik, {Yashpal S.} and Deepak Kumar and Singh, {Raj K.} and Iqbal, {Hafiz M.N.} and Sunil Joshi",
year = "2017",
month = "8",
day = "3",
doi = "10.3389/fmicb.2017.01469",
language = "English (US)",
volume = "8",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Advances in developing therapies to combat zika virus

T2 - Current knowledge and future perspectives

AU - Munjal, Ashok

AU - Khandia, Rekha

AU - Dhama, Kuldeep

AU - Sachan, Swati

AU - Karthik, Kumaragurubaran

AU - Tiwari, Ruchi

AU - Malik, Yashpal S.

AU - Kumar, Deepak

AU - Singh, Raj K.

AU - Iqbal, Hafiz M.N.

AU - Joshi, Sunil

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international "public health emergency" in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barré syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV.

AB - Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international "public health emergency" in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barré syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV.

KW - Drugs

KW - Guillain-Barré Syndrome

KW - Microcephaly

KW - Therapies

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85026836080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026836080&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2017.01469

DO - 10.3389/fmicb.2017.01469

M3 - Review article

AN - SCOPUS:85026836080

VL - 8

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - AUG

M1 - 1469

ER -